Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this doubleblind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5 mg dutasteride once daily, 0.4 mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (Po0.05), and numerically, but not statistically significantly, greater compared with dutasteride. Mean IPSS was reduced from baseline by 7.5 (±0.84) in the combination group, by 6.3 (±0.86) in the dutasteride group and by 4.5 (±0.78) in the tamsulosin group, resulting in respective mean IPSS at months 24 of 11.4 (±0.60), 12.7 (±0.70) and 14.3 ( ± 0.74). The adverse event profile was similar to that observed in the overall CombAT population, and drug-related adverse events were more common with combination therapy (26%) than with tamsulosin (15%) or dutasteride (9%). No unexpected adverse events emerged. In conclusion, in Asian men with moderate-to-severe lower urinary tract symptoms and an enlarged prostate, combination therapy achieved significantly greater improvements from baseline BPH symptoms, flow rate, quality of life, reduced prostate volume and improved treatment satisfaction compared with tamsulosin monotherapy.
Introduction
Symptoms of benign prostatic hyperplasia (BPH) affect approximately 50% of men aged 50 years or older, increasing to 90% of men aged 70 years and above. 1 The prevalence of lower urinary tract symptoms (LUTS) varies not only with age but also geographically. For example, moderate-to-severe LUTS are more prevalent in Asia and China than in Western countries, [2] [3] [4] [5] and prostate volume and prostate-specific antigen (PSA) levels have been reported to be lower in men of Asian ethnicity and living in Asia and the Far East than in Western and Caucasian men, [6] [7] [8] [9] [10] although not all studies agree. 11, 12 Despite reported ethnic differences in prostate size and physiology, it is believed that the disease presentation is similar in Asian and Western men. The patient populations in large BPH treatment trials are predominantly Caucasian and it is generally assumed that results in the overall population can be extrapolated to the smaller ethnic subgroups in the study.
Symptoms of BPH result from outlet obstruction due to enlarged prostate, and proliferation of prostate tissue is under control of dihydrotestosterone (DHT), which is produced in the prostate from testosterone by the 5a-reductase (5AR) enzymes (type I and type II). 13 BPH is progressive in nature, and the goals of BPH management are to relieve symptoms and to slow long-term progression of disease to prevent potentially serious complications such as acute urinary retention (AUR) and the need for surgery.
The two main drug classes used for BPH treatment are the a-blockers and the 5AR inhibitors (5ARIs). a-Blockers improve symptoms by rapidly reducing smooth muscle tone in the prostate and bladder neck but have no effect on prostate enlargement and therefore do not affect disease progression. 5ARIs target the underlying pathology of BPH by inhibiting the production of DHT and, by reducing prostate volume, treat LUTS and attenuate disease progression. However, it takes a few months before clinical improvement is apparent. [14] [15] [16] [17] [18] [19] [20] [21] [22] The value of combination therapy with 5ARIs and ablockers over monotherapy with either drug was first demonstrated in the Medical Therapy Of Prostatic Symptoms (MTOPS) study. 23 In men with BPH, combination therapy with finasteride and doxazosin was superior to each monotherapy at 4 years for treatment of LUTS and reducing risk of progression. 23 The CombAT study was designed to build on this knowledge, focusing on men with moderate-to-severe LUTS and at increased risk of BPH progression (symptomatic BPH and prostate volume X30 cm 3 ). 24, 25 Two-year results from CombAT demonstrated superior improvement in LUTS with combination treatment, compared with monotherapy with either dutasteride or tamsulosin. 24 This article reports a post hoc analysis of the 2-year efficacy and safety of combined therapy with the 5ARI dutasteride and the a-blocker tamsulosin, compared with each agent alone, in Asian men with symptomatic BPH and enlarged prostate (X30 cm 3 ). These men were a subpopulation of those participating in the 4-year CombAT study. 24, 25 The aim of this analysis was to determine whether men in this ethnic group, achieve treatment responses in line with those seen in the overall study population of men with moderate-to-severe LUTS and prostate enlargement.
Methods

Design and interventions
CombAT is a 4-year, double-blind, randomized, parallelgroup study. The study design and rationale, 25 and efficacy and safety results from the planned 2-year analysis, 24 have been reported previously. Following screening for inclusion, eligible participants underwent a 4-week placebo run-in and were then allocated to treatment groups in a 1:1:1 ratio, according to a computer-generated randomization schedule. Patients in the combination group received 0.5 mg dutasteride once daily plus 0.4 mg tamsulosin once daily; patients in the dutasteride group received 0.5 mg dutasteride once daily plus placebo tamsulosin once daily; patients in the tamsulosin group received 0.4 mg tamsulosin once daily and placebo dutasteride once daily. Patients in all groups self-administered the drugs (or placebo), and were blinded as to the intervention.
The study was conducted according to good clinical practice guidelines and with the approval of local Ethics Committees, Institutional Review Boards, and regulatory authorities. Informed consent was obtained for all subjects, and the studies were performed in accordance with the version of the Declaration of Helsinki that applied at the time the studies were conducted.
Participants
A total of 450 centers are participating in the ongoing CombAT trial, including outpatient clinics, hospital clinics and general surgery practices in 34 countries across Europe, North America, Latin America and Asia Pacific. The study enrolled men X50 years with a clinical diagnosis of BPH, by medical history and physical examination (including digital rectal examination). Other inclusion criteria were international prostate symptom score (IPSS) X12 points, prostate volume X30 cm 3 (by transrectal ultrasound (TRUS)), total serum PSA X1.5 and p10 ng ml À1 , two voids at screening with Q max 45 and p15 ml s
À1
, with a minimum voided volume X125 ml. Exclusion criteria included history or evidence of prostate cancer, previous prostate surgery, a history of AUR within 3 months of screening visit and use of any 5ARI within 6 months or any a-blockers within 2 weeks of the screening visit.
The 325 participants who defined their ethnicity as 'Asian' are included in this post hoc analysis. Of these, 285 (88%) men were located in Asian countries (South Korea, Philippines, Taiwan, Thailand). The remaining 12% were resident in Western countries (Canada, South Africa, United Kingdom, USA; Table 1 ) and may have been firstgeneration, second-generation or long-term residents.
Outcome measures
For the planned analysis at 2 years, the primary endpoint was change in IPSS from baseline for combination treatment vs each monotherapy. Secondary endpoints included change from baseline in Q max , prostate volume, BPH impact index (BII), IPSS question 8 and the patient perception of study medication (PPSM) questionnaire. All endpoints were assessed at baseline (after completing the placebo run-in period), and at each 3-month visit. The percentage of patients classified as 'responders' was calculated for various definitions of responder for IPSS and for Q max . Three criteria were used to define IPSS responders: X25% improvement in IPSS score, X2-point improvement and X3-point improvement. Q max responders were defined as those patients achieving X30% or X3 ml s À1 improvement in Q max . The BII is a four-item patient-completed questionnaire that measures the impact of BPH symptoms on physical discomfort, worry about health, degree of bother, and limitations of daily activities. Possible scores range from 0 (no impact) to 13 (highest negative impact). Question 8 of the IPSS asks 'if you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?' Possible scores range from 0 (delighted) to 6 (terrible). The PPSM is a 12-item questionnaire that assesses patient satisfaction with treatment in domains including control of urinary problems, strength of urinary stream, pain during urination, interference with usual activities (items 1-10), overall satisfaction with medication (item 11, 'Overall, how satisfied are you with the study medication and its effects on your urinary problems?'), and intent to ask for the study medication again (item 12). 26 
Safety measurements
Adverse events were recorded at every 3-month visit. Prostate cancer diagnoses were recorded as part of the study protocol and TRUS-guided prostate biopsies for prostate cancer could be performed during the study at investigator discretion.
Statistical analysis
The population analyzed in this report was the intent-totreat (ITT) population of subjects who reported their ethnicity as 'Asian' (n ¼ 325). A last-observation-carriedforward (LOCF) approach was used. The total number of participants enrolled in the CombAT study was calculated to provide appropriate power to detect differences between treatment groups at Po0.01. 25 This post hoc analysis compares mean changes from baseline in the combination group with each monotherapy group, using a two-sided P-value of o0.05 to determine statistical significance. The change in IPSS from baseline was compared at each post-baseline assessment for combination therapy vs each monotherapy using a general linear model with effects for treatment, investigative site cluster and baseline IPSS. Unless otherwise indicated, data are presented as mean ± standard error.
Results
Subject demographics and disposition
Of the 325 Asian men randomly assigned to treatment groups (the ITT population), 280 (86%) completed the month-24 visit, and there were comparable rates of discontinuation in the three treatment groups (Figure 1) .
The Asian ITT population consisted of men enrolled at study sites in South Korea, the Philippines, Taiwan and Thailand, as well as Asian men in Canada, South Africa, the United Kingdom and the United States of America (Table 1) . The demographics and baseline characteristics of Asian men and of the total study population are shown in Table 2 .
Primary endpoints
At month 24, decrease in IPSS from baseline was significantly greater with combination treatment compared with tamsulosin (Po0.05). Mean IPSS was reduced from baseline by 7.5 ( ± 0.84) in the combination group, by 6.3 (±0.86) in the dutasteride group and by 4.5 ( ± 0.78) in the tamsulosin group. These reductions resulted in a mean IPSS at 24 months of 11.4 (±0.60) in the combination group, 12.7 ( ± 0.70) in the dutasteride group and 14.3 (±0.74) in the tamsulosin group (Figure 2) .
Symptom improvement from baseline with combination therapy was significantly greater than with tamsulosin from month 9 through to month 24 (Po0.05), and numerically greater than with dutasteride at all time points. ), improvement in IPSS was numerically greater at month 24, with combination treatment (À6.9±1.26) than with dutasteride (À6.1±1.27) and tamsulosin (À5.6 ± 1.19) monotherapies, but the differences were not statistically significant. In patients with prostate volume X43 cm 3 , improvement in IPSS at month 24 was significantly greater with combination treatment (À8.4 ± 1.15) compared with tamsulosin (À3.8±1.05; Po0.05) and numerically greater than dutasteride (À6.7 ± 1.18). The statistical significance of IPSS improvement with combination vs tamsulosin at month 24 was maintained in patients with below median PSA (o3.6 ng ml À1 ) and above median PSA (X3.6 ng ml À1 ).
Secondary endpoints Q max . At month 24, Q max improved from baseline by 2.1 ( ± 0.59) ml s À1 in the combination group, 0.9 (±0.6) ml s À1 in the dutasteride group, and 0.2 (±0.54) ml s À1 in the tamsulosin group (Po0.05 combination vs tamsulosin). These improvements resulted in a mean Q max at 2 years of 13.4 (±0.43) ml s À1 in the combination group, 11.6 ( ± 0.51) ml s À1 in the dutasteride group and 11.3 (±0.40) ml s À1 in the tamsulosin group. Q max improvement from baseline with combination therapy was significantly greater than with tamsulosin from month 12 through to month 24 (Po0.05).
IPSS and Q max responders. For all three criteria used to define IPSS responders, response rates at month 24 were numerically greater in the combination group than the dutasteride group, and in the dutasteride group than the tamsulosin group. This difference reached statistical significance for the IPSS responder category defined by X2-point improvement in IPSS: the response rate was significantly higher in the combination group (74%) than in the tamsulosin group (55%; Po0.05), and numerically higher than in the dutasteride group (67%; Figure 3 ). 
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On both Q max responder criteria, there were more responders in the combination group than the dutasteride group, and more in the dutasteride group than in the tamsulosin group. The percentage of patients who achieved X3 ml s À1 improvement in Q max at month 24 was 36% in the combination group, 32% in the dutasteride group and 23% in the tamsulosin group (combination vs tamsulosin, Po0.05).
Prostate volume. At month 12 and month 24, the mean percentage reduction in prostate volume from baseline was significantly greater for both combination treatment and dutasteride monotherapy, compared with tamsulosin monotherapy (Figure 4) . The mean percentage reduction in prostate volume from baseline at 12 months was 25.7±2.87% with combination treatment (Po0.05 vs tamsulosin), 28.7 ± 2.89% with dutasteride monotherapy and 0.4±3.59% with tamsulosin monotherapy. At 24 months, the mean percentage reduction in prostate volume from baseline was 30.5 ± 2.67% with combination (Po0.05 vs tamsulosin), 28.6 ± 2.85% with dutasteride and 0.7 ± 3.54% with tamsulosin.
BPH impact index. At month 24, BII improved from baseline by 2.6 ( ± 0.37) in the combination group, by 2.1 (±0.38) in the dutasteride group and by 1.5 (±0.34) in the tamsulosin group. These improvements resulted in a mean BII at month 24 of 3.8 (±0.3) in the combination group, 4.1 ( ± 0.28) in the dutasteride group and 5.0 (±0.31) in the tamsulosin group. The reduction in BII with combination therapy was significantly greater than with tamsulosin monotherapy (Po0.05).
BPH-related health status. At month 24, the BPHrelated health status score (IPSS Q8) improved from baseline by 1.7 (±0.19), 1.3 (±0.2) and 1.1 (±0.18) in the combination, dutasteride and tamsulosin groups, respectively. These improvements resulted in a mean score at month 24 of 2.1 ( ± 0.14) in the combination group, 2.6 (±0.15) in the dutasteride group and 2.8 (±0.15) in the tamsulosin group. The reduction in BPH-related health status score at month 24 with combination therapy was significantly greater than with tamsulosin (Po0.05) and than with dutasteride (Po0.05) monotherapy.
Patient perception of study medication. For each of the 12 questions in the PPSM questionnaire, an equal or higher percentage of patients in the combination group responded positively compared with the dutasteride and tamsulosin groups. On the overall satisfaction score (item 11), 91% of patients receiving combination therapy reported satisfaction (very satisfied, satisfied or somewhat satisfied), compared with 84% of dutasteride patients and 80% of tamsulosin patients (Po0.05, combination vs tamsulosin).
Safety and tolerability
The overall incidence of adverse events was similar in the three treatment groups (77% combination, 76% dutasteride, 79% tamsulosin), as was the incidence of serious adverse events (12, 17 and 18%) (Table 3) . Adverse events considered to be drug-related were more common in the combination group (26%) than in either monotherapy group (dutasteride, 9%; tamsulosin, 15%); the most common drug-related adverse events are shown in Table 3 . Drug-related adverse events led to withdrawal or discontinuation from the study in 4.7% of patients in the combination group, o1% in the dutasteride group and 2.7% in the tamsulosin group.
Prostate cancer was reported in four men: two men in the tamsulosin group (1.8%) and one man each in the combination group and the dutasteride group (o1%). These events were not considered to be related to study medication. Other than prostate cancer, the most common serious adverse events were inguinal hernia (combination, 0.9%; dutasteride, 0.9%; tamsulosin, 2.7%), and coronary artery disease (combination, 0.9%; dutasteride, 0.9%; tamsulosin, 1.8%). There was one serious and drug-related adverse event reported in the tamsulosin group (circulatory collapse). No incidences of floppy iris syndrome or breast neoplasms were reported. Combination treatment reduced total serum PSA by an average of 54.0% (±2.06), dutasteride reduced PSA by 48.8% ( ± 2.91), and total serum PSA increased by 21.2% (±5.19) in the tamsulosin group. 
Discussion
In Asian men with moderate-to-severe LUTS and an enlarged prostate, combination treatment with dutasteride and tamsulosin significantly improved LUTS, urinary flow rate and reduced prostate volume compared with tamsulosin monotherapy. Combination treatment also improved quality of life measures compared with either monotherapy, and more patients were satisfied with combination treatment than with tamsulosin monotherapy. Improvement in IPSS from baseline was significantly greater with combination than with tamsulosin monotherapy from month 9, and Q max from month 12. Although 75% of patients in this Asian population had previously received a-blocker therapy, response rate to combination treatment was high. Of all patients taking combination therapy, at 24 months, 74% responded with an improvement of at least 2 IPSS units, compared with a response rate of 55% in the tamsulosin group. No unexpected adverse events emerged in this population and adverse events considered to be drug related were in line with those expected for each monotherapy.
The results presented here are in line with those in the overall CombAT study population. In the overall population, IPSS was reduced from baseline by 6.2, 4.9 and 4.3 in the combination, dutasteride and tamsulosin groups respectively; 24, 25 IPSS reductions from baseline in this Asian subpopulation were 7.5 (combination), 6.3 (dutasteride) and 4.5 (tamsulosin). It is worth noting that the IPSS improvement in Asian men was numerically greater compared to the overall population in the combination and dutasteride groups, but not in the tamsulosin group. One reason might be the fact that 75% of the Asian men had prior exposure to a-blocker therapy compared with only 50% of the overall population, which may blunt the response to tamsulosin treatment.
The eight drug-related adverse events that occurred in X1% of any treatment group in the Asian population matched those seen in the overall CombAT population. In this Asian population, similar to the overall CombAT population, the incidence of sexual side effects was higher in the combination group than in either monotherapy group. This may reflect the fact that both drugs expose patients to unique sexually related side effects, which when combined, cause more than just additive, perhaps synergistic, effects. For example, the reduction in ejaculate volume, a known adverse event of 5ARIs, 22, 23 coupled with the retrograde ejaculation that is associated with tamsulosin, [27] [28] [29] may explain the increased perception of sexual dysfunction. In this study, only one subject (combination treatment group) was withdrawn from the study due to a sexual-related adverse event (decreased libido). This is the first publication to report the effectiveness of combination treatment (5ARI and a-blocker) compared with monotherapies in a significant Asian population (n ¼ 325). The previous long-term, randomized, controlled trial investigating combination treatment (finasteride and doxazosin) for BPH did not have a significant Asian population. In the MTOPS study, 82.5% of participants were white, 9% black, 7% Hispanic and 1.5% other. 23 There are also limited data on monotherapy with 5ARIs or a-blockers in Asian men. Studies have demonstrated the efficacy of doxazosin, tamsulosin and terazosin in populations (n ¼ 27-205) including Korean, Japanese and Chinese men. [30] [31] [32] [33] [34] [35] These studies used a dose of 0.2 mg tamsulosin, whereas the CombAT study used 0.4 mg, with no unexpected safety or tolerability issues compared to studies using the 0.2 mg dose. Efficacy of the 5ARI finasteride has also been studied in Asian men, demonstrating reduced prostate volume, and improvement in symptoms and Q max at 6 months and 1 year. 32, 36 It should be noted that the analysis of data in the Asian subpopulation of the CombAT study was not prospectively planned and therefore has limitations inherent to all post hoc analyses. First, the relatively small size of this subgroup, compared with the overall study population, limits its statistical power. For the primary endpoint and many secondary endpoints, the difference between combination therapy and dutasteride monotherapy did not reach statistical significance, whereas the same comparisons in the overall CombAT population revealed statistically significant differences. Second, in a post hoc comparison of this nature, statistical comparisons between the monotherapy groups have limited validity. It is also not possible to determine how the effects of dutasteride or tamsulosin monotherapy in the Asian subgroup compare with their effects in the overall study population.
Differences in prostate volume between men of Asian descent and Western men have been suggested to decline when Asian men migrate to Western or Westernized societies. 9 Therefore, it is interesting to note that the majority of Asian men in this analysis (88%) were resident in Asian countries (Korea, Philippines, Taiwan and Thailand). The remaining 12% were resident in Canada, South Africa, the United Kingdom and the United States. At baseline, mean symptom scores, Q max and PV were similar across the treatment groups in the overall and Asian populations and indicative of a population with moderate-to-severe bothersome symptoms and enlarged prostates. Although this study was not designed to compare prostate volume and PSA levels between the Asian subpopulation and the overall CombAT population, the observed mean prostate volumes at baseline in Asian men appeared to be numerically smaller than that in the overall population (47.7 vs 54.7 cm 3 in the combination group; 48.8 vs 54.6 cm 3 in the dutasteride group; 48.1 vs 55.8 cm 3 in the tamsulosin group). In contrast, serum PSA levels were similar in the Asian population and the overall population (4.1 vs 4.0 ng ml À1 ). This is in line with previous studies showing smaller prostate glands but similar PSA levels in Asian compared with Western men. 8, 9, [37] [38] [39] [40] We found that in the total Asian population, combination treatment maintained its superior reduction in IPSS compared with both monotherapies, although differences were less pronounced in men with the smallest prostate enlargement. A key consideration is how these observations fit with our understanding of prostate gland physiology and suggested differences between prostate sizes of Asian and Caucasian men. It is generally acknowledged that the efficacy of 5ARIs is greater in men with enlarged prostates. 41 The majority of evidence suggests that Asian men have smaller prostates than Caucasians 8, 9 (although not all studies agree 42 ), and therefore the precise definition of enlarged prostate will Dutasteride/tamsulosin combination in Asian men B-H Chung et al differ in this population. However, our results show that in Asian men with clinically enlarged prostate and LUTS, combination therapy retains its ability to improve symptoms of BPH despite a potentially smaller absolute prostate volume.
Several observations of prostate anatomy and physiology have potential relevance to this finding. Differences in prostate volume between Asian and Caucasian Western men may be accounted for almost entirely by central prostate volume, which includes the anatomical transitional zone, where the nodules of benign prostatic hyperplasia are thought to originate. 9, 43 In accordance with a reduced prostate volume but similar PSA levels, PSA density (amount of PSA per unit volume of prostate) is higher in Asian men [37] [38] [39] [40] and this is possibly explained by differences in cellular composition of the prostate. 44 As prostate size increases, glands tend to contain relatively less smooth muscle and relatively more epithelium. 45 In Korean men with symptomatic BPH, prostates with a volume of less than 80 cm 3 had higher relative smooth muscle composition compared with prostates larger than 80 cm 3 , suggesting that the dynamic component of LUTS may be more prominent in men with smaller prostates. Other potential factors reported underlying the variation in BPH symptoms and prostate size with ethnicity may include environmental factors 9 or genetic influence. 46, 47 As decision-making for BPH treatment is based on factors such as prostate volume and PSA level, in addition to clinical presentation, it remains to be determined whether ethnic-specific guidelines for cutoffs are required. 48 
Conclusion
These data indicate that Asian men with moderate-tosevere LUTS and an enlarged prostate benefit from combination treatment with dutasteride and tamsulosin. In line with results in the overall CombAT population, combination therapy significantly improved symptoms, flow rate, quality of life, reduced prostate volume and improved treatment satisfaction compared with tamsulosin monotherapy. The 4-year data from the CombAT study will provide information on the long-term effect of combination treatment on symptoms of BPH and other outcomes, such as AUR and the need for BPH-related surgery.
